ChromaDex unveils intravenous and injectable NAD+ booster

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Company’s new Niagen+ IV treatment claimed to raise NAD+ levels higher and faster than conventional IV therapies.

Healthy aging bioscience company ChromaDex has introduced Niagen+, a pharmaceutical-grade intravenous and injectable form of Niagen, the company’s patented form of NAD+ precursor nicotinamide riboside (NR). The product will be available in IV, shot and push forms at select clinics with a prescription starting this summer.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LT Staff

Longevity.Technology's in-house writing staff.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE